Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.

Background: Chemotherapy is a standard therapeutic regimen to treat triple-negative breast cancer (TNBC); however, chemotherapy alone does not result in significant improvement and often leads to drug resistance in patients. In contrast, combination therapy has proven to be an effective strategy for...

Descripción completa

Detalles Bibliográficos

Publicado en:	Breast Cancer Research Vol. 21; no. 1
Autores principales:	Lee, Jung Ok, Kang, Min Ju, Byun, Won Seok, Kim, Shin Ae, Seo, Il Hyeok, Han, Jeong Ah., Moon, Ji Wook, Kim, Ji Hae, Kim, Su Jin, Lee, Eun Jung, In Park, Serk, Park, Sun Hwa, Kim, Hyeon Soo
Formato:	Journal Article
Publicado:	BioMed Central 10/22/2019
Acceso en línea:	Ver este registro en EBSCOhost